Caregen Co., Ltd.

KOSDAQ:A214370 Stock Report

Market Cap: ₩1.4t

Caregen Past Earnings Performance

Past criteria checks 1/6

Caregen has been growing earnings at an average annual rate of 8.1%, while the Pharmaceuticals industry saw earnings growing at 7.5% annually. Revenues have been growing at an average rate of 7% per year. Caregen's return on equity is 16.2%, and it has net margins of 45.5%.

Key information

8.1%

Earnings growth rate

8.5%

EPS growth rate

Pharmaceuticals Industry Growth11.3%
Revenue growth rate7.0%
Return on equity16.2%
Net Margin45.5%
Last Earnings Update30 Sep 2024

Recent past performance updates

Why Caregen's (KOSDAQ:214370) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 21
Why Caregen's (KOSDAQ:214370) Shaky Earnings Are Just The Beginning Of Its Problems

Caregen (KOSDAQ:214370) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Mar 18
Caregen (KOSDAQ:214370) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Recent updates

Earnings Not Telling The Story For Caregen Co., Ltd. (KOSDAQ:214370) After Shares Rise 29%

Dec 20
Earnings Not Telling The Story For Caregen Co., Ltd. (KOSDAQ:214370) After Shares Rise 29%

Why Caregen's (KOSDAQ:214370) Shaky Earnings Are Just The Beginning Of Its Problems

Nov 21
Why Caregen's (KOSDAQ:214370) Shaky Earnings Are Just The Beginning Of Its Problems

Why We're Not Concerned Yet About Caregen Co., Ltd.'s (KOSDAQ:214370) 26% Share Price Plunge

Aug 06
Why We're Not Concerned Yet About Caregen Co., Ltd.'s (KOSDAQ:214370) 26% Share Price Plunge

Caregen (KOSDAQ:214370) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

Mar 18
Caregen (KOSDAQ:214370) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of

With Caregen Co., Ltd. (KOSDAQ:214370) It Looks Like You'll Get What You Pay For

Mar 05
With Caregen Co., Ltd. (KOSDAQ:214370) It Looks Like You'll Get What You Pay For

A Look At The Fair Value Of Caregen Co., Ltd. (KOSDAQ:214370)

Apr 20
A Look At The Fair Value Of Caregen Co., Ltd. (KOSDAQ:214370)

Here's How We Evaluate Caregen Co., Ltd.'s (KOSDAQ:214370) Dividend

Mar 02
Here's How We Evaluate Caregen Co., Ltd.'s (KOSDAQ:214370) Dividend

Caregen (KOSDAQ:214370) Is Growing Earnings But Are They A Good Guide?

Feb 04
Caregen (KOSDAQ:214370) Is Growing Earnings But Are They A Good Guide?

Do Its Financials Have Any Role To Play In Driving Caregen Co., Ltd.'s (KOSDAQ:214370) Stock Up Recently?

Jan 14
Do Its Financials Have Any Role To Play In Driving Caregen Co., Ltd.'s (KOSDAQ:214370) Stock Up Recently?

Caregen Co., Ltd. (KOSDAQ:214370) Goes Ex-Dividend Soon

Dec 25
Caregen Co., Ltd. (KOSDAQ:214370) Goes Ex-Dividend Soon

Do Insiders Own Lots Of Shares In Caregen Co., Ltd. (KOSDAQ:214370)?

Dec 10
Do Insiders Own Lots Of Shares In Caregen Co., Ltd. (KOSDAQ:214370)?

Is Caregen Co., Ltd. (KOSDAQ:214370) A Great Dividend Stock?

Nov 19
Is Caregen Co., Ltd. (KOSDAQ:214370) A Great Dividend Stock?

Revenue & Expenses Breakdown

How Caregen makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

KOSDAQ:A214370 Revenue, expenses and earnings (KRW Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2478,66835,79110,9206,702
30 Jun 2477,06733,89410,8376,288
31 Mar 2474,98735,30510,8715,855
31 Dec 2379,21039,93010,2755,824
30 Sep 2380,90537,33210,4696,147
30 Jun 2380,49833,81411,3957,610
31 Mar 2378,47633,88511,0466,677
31 Dec 2269,09827,26710,7996,285
30 Sep 2264,98825,73910,2786,616
30 Jun 2260,32726,01810,0764,760
31 Mar 2259,17925,16310,4854,931
31 Dec 2159,08825,31810,8085,026
30 Sep 2161,57031,65211,7283,576
30 Jun 2162,63931,57910,7983,804
31 Mar 2161,53732,15610,6704,079
31 Dec 2060,29531,47811,3743,839
30 Sep 2063,72028,3639,4984,704
30 Jun 2063,81728,35610,4964,360
31 Mar 2063,35727,39413,0894,152
31 Dec 1964,69928,07012,5184,297
30 Sep 1949,39913,61812,8884,413
30 Jun 1946,89712,12011,6244,111
31 Mar 1952,82017,6078,5833,808
31 Dec 1851,21116,4918,1643,627
30 Sep 1852,53124,4016,6662,675
30 Jun 1851,96524,5567,2592,784
31 Mar 1850,14423,2817,8863,006
31 Dec 1746,53118,4267,9123,023
30 Sep 1739,46915,3779,0123,599
30 Jun 1734,78411,4128,4013,426
31 Mar 1732,6689,6557,5433,417
31 Dec 1630,90511,5697,6373,253
30 Jun 1635,43815,4047,3682,911
31 Dec 1530,23412,8116,5362,251

Quality Earnings: A214370 has a high level of non-cash earnings.

Growing Profit Margin: A214370's current net profit margins (45.5%) are lower than last year (46.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: A214370's earnings have grown by 8.1% per year over the past 5 years.

Accelerating Growth: A214370's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: A214370 had negative earnings growth (-4.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (22.3%).

Return on Equity

High ROE: A214370's Return on Equity (16.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 18:40
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Caregen Co., Ltd. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Byung Hwa HanEugene Investment & Securities Co Ltd.
Brian ChoHSBC
Sang-Hun LeeiM Securities